Krystal Biotech (NASDAQ:KRYS) PT Raised to $206.00

Krystal Biotech (NASDAQ:KRYS) had its price target lifted by equities research analysts at Evercore ISI from $201.00 to $206.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Evercore ISI’s price objective would suggest a potential upside of 9.88% from the company’s current price.

Other equities analysts have also issued reports about the company. Chardan Capital boosted their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Citigroup restated a “neutral” rating and set a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Krystal Biotech in a report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $187.89.

Krystal Biotech Trading Up 1.7 %

Shares of KRYS stock opened at $187.47 on Monday. The firm has a market capitalization of $5.35 billion, a P/E ratio of 100.25 and a beta of 0.84. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34. The firm’s fifty day simple moving average is $188.00 and its 200 day simple moving average is $166.53.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. The business’s revenue for the quarter was up 70283900.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.25) earnings per share. Equities research analysts anticipate that Krystal Biotech will post 2 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the transaction, the insider now directly owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Julian S. Gangolli sold 20,000 shares of Krystal Biotech stock in a transaction on Monday, May 20th. The shares were sold at an average price of $164.13, for a total value of $3,282,600.00. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KRYS. Jamison Private Wealth Management Inc. bought a new position in shares of Krystal Biotech in the second quarter worth about $28,000. GAMMA Investing LLC raised its position in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the last quarter. Key Financial Inc acquired a new position in Krystal Biotech during the 2nd quarter worth $28,000. Blue Trust Inc. boosted its position in Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at $71,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).